Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Obeticholic acid
Drug ID BADD_D01592
Description Primary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation.[A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival.[A18696] In 2016, it was granted approval to treat primary biliary cholangitis in combination with [ursodeoxycholic acid], which was previously the mainstay treatment for this condition.[A18696,L12633] In May 2021, the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or hepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation.[L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH). The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636]
Indications and Usage Obeticholic acid was approved as an orphan drug based on its reduction in the level of the biomarker alkaline phosphatase as a surrogate endpoint for clinical benefit. It is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Additional studies are being required to prove its clinical benefit.
Marketing Status Prescription
ATC Code A05AA04
DrugBank ID DB05990
KEGG ID D09360
MeSH ID C464660
PubChem ID 447715
TTD Drug ID D0M4WA
NDC Product Code 73435-004; 63190-0840; 47848-056; 65089-0055; 0009-0098; 69766-066; 59285-028; 71796-004; 46708-923; 63190-0830; 69516-010; 68554-0121; 69516-005
Synonyms obeticholic acid | 6ECDCA | cholan-24-oic acid, 6-ethyl-3,7-dihydroxy-, (3alpha,5beta,6alpha,7alpha)- | 6alpha-ethyl-3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid | 6-ECDCA | 6alpha-ethyl-chenodeoxycholic acid | 6-ethyl-3,7-dihydroxycholan-24-oic acid | 6-ethyl chenodeoxycholic acid | 6-ethylchenodeoxycholic acid | DSP-1747 | DSP1747 | Ocaliva | INT 747 | INT747 | INT-747
Chemical Information
Molecular Formula C26H44O4
CAS Registry Number 459789-99-2
SMILES CCC1C2CC(CCC2(C3CCC4(C(C3C1O)CCC4C(C)CCC(=O)O)C)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lower limb fracture12.04.01.004; 15.08.03.0040.004205%Not Available
Disease progression08.01.03.038--
Drug intolerance08.06.01.0130.018921%Not Available
Hepatic lesion09.01.08.0050.004205%Not Available
Peritonitis bacterial11.02.01.023; 07.19.05.0030.001097%Not Available
Renal impairment20.01.03.010--Not Available
Unevaluable event08.01.03.0510.012614%Not Available
Hepatic enzyme abnormal13.03.01.0200.004205%Not Available
Bowel movement irregularity07.02.03.0030.004205%Not Available
Skin haemorrhage23.06.07.001; 24.07.06.0090.010512%Not Available
Localised intraabdominal fluid collection07.07.01.0070.006307%Not Available
Vulvovaginal burning sensation21.08.02.0070.004205%Not Available
Anorectal discomfort07.03.03.0030.004205%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.029433%
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.001097%Not Available
Liver function test increased13.03.01.0440.008410%Not Available
Tibia fracture15.08.03.016; 12.04.01.0160.004205%Not Available
Concomitant disease progression08.01.03.0640.001645%Not Available
Clostridium difficile infection11.02.02.0090.006307%Not Available
Child-Pugh-Turcotte score increased13.03.01.0460.004205%Not Available
The 8th Page    First    Pre   8    Total 8 Pages